Subtopic Deep Dive
HIV Integrase Inhibitors
Research Guide
What is HIV Integrase Inhibitors?
HIV Integrase Inhibitors are antiretroviral drugs that block the strand transfer step of HIV-1 integrase, preventing viral DNA integration into the host genome.
Strand transfer inhibitors like raltegravir and dolutegravir target the integrase enzyme essential for HIV replication (Hazuda et al., 2000, 1125 citations). These inhibitors show high potency in cells and clinical settings (Summa et al., 2008, 624 citations). Over 10 key papers from 2000-2022 detail their discovery, mechanisms, and resistance profiles.
Why It Matters
HIV Integrase Inhibitors form the backbone of modern combination antiretroviral therapy, enabling viral suppression to undetectable levels in most patients (Arts and Hazuda, 2012, 837 citations; Günthard et al., 2016, 644 citations). Raltegravir's discovery provided the first approved integrase inhibitor, transforming treatment regimens (Summa et al., 2008). Dolutegravir offers a high barrier to resistance, reducing treatment failure rates, though weight gain risks require monitoring (Sax et al., 2019, 716 citations). These drugs support pre-exposure prophylaxis, preventing new infections (Saag et al., 2018, 549 citations).
Key Research Challenges
Resistance Mutations
Mutations in the integrase gene reduce inhibitor efficacy, complicating long-term therapy (Pommier et al., 2005, 682 citations). Primary resistance emerges in up to 10% of treatment-experienced patients. Secondary mutations further lower susceptibility to dolutegravir (Hare et al., 2010, 657 citations).
Weight Gain Side Effects
Initiation of integrase inhibitors like dolutegravir links to rapid weight gain in clinical trials (Sax et al., 2019, 716 citations). Factors include baseline BMI and regimen switches. This increases obesity risk in treated populations (Günthard et al., 2016).
Allosteric Inhibition Design
Strand transfer inhibitors dominate, but allosteric sites offer new targets for multi-drug resistance evasion (Hazuda et al., 2000). Structural studies reveal intasome assembly challenges (Hare et al., 2010, 657 citations). Few candidates advance to clinic due to potency issues.
Essential Papers
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Daria J. Hazuda, Peter J. Felock, Marc Witmer et al. · 2000 · Science · 1.1K citations
Integrase is essential for human immunodeficiency virus–type 1 (HIV-1) replication; however, potent inhibition of the isolated enzyme in biochemical assays has not readily translated into antiviral...
HIV-1 Antiretroviral Drug Therapy
Eric J. Arts, Daria J. Hazuda · 2012 · Cold Spring Harbor Perspectives in Medicine · 837 citations
The most significant advance in the medical management of HIV-1 infection has been the treatment of patients with antiviral drugs, which can suppress HIV-1 replication to undetectable levels. The d...
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul E. Sax, Kristine M. Erlandson, Jordan E. Lake et al. · 2019 · Clinical Infectious Diseases · 716 citations
Abstract Background Initiation of antiretroviral therapy (ART) often leads to weight gain. While some of this weight gain may be an appropriate return-to-health effect, excessive increases in weigh...
Integrase inhibitors to treat HIV/Aids
Yves Pommier, Allison A. Johnson, Christophe Marchand · 2005 · Nature Reviews Drug Discovery · 682 citations
Retroviral intasome assembly and inhibition of DNA strand transfer
S. Hare, Saumya Gupta, Eugene Valkov et al. · 2010 · Nature · 657 citations
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Huldrych F. Günthard, Michael S. Saag, Constance A. Benson et al. · 2016 · JAMA · 644 citations
Antiretroviral agents remain the cornerstone of HIV treatment and prevention. All HIV-infected individuals with detectable plasma virus should receive treatment with recommended initial regimens co...
Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
Vincenzo Summa, Alessia Petrocchi, Fabio Bonelli et al. · 2008 · Journal of Medicinal Chemistry · 624 citations
Human immunodeficiency virus type-1 (HIV-1) integrase is one of the three virally encoded enzymes required for replication and therefore a rational target for chemotherapeutic intervention in the t...
Reading Guide
Foundational Papers
Start with Hazuda et al. (2000, 1125 citations) for strand transfer inhibitor validation in cells; Summa et al. (2008, 624 citations) for raltegravir discovery; Pommier et al. (2005, 682 citations) for mechanism overview.
Recent Advances
Günthard et al. (2016, 644 citations) and Saag et al. (2018, 549 citations) for clinical guidelines; Sax et al. (2019, 716 citations) for weight gain risks; Gandhi et al. (2022, 514 citations) for updated recommendations.
Core Methods
Strand transfer biochemical assays (Hazuda et al., 2000); intasome cryo-EM/ crystallography (Hare et al., 2010); resistance genotyping and fitness assays (Arts and Hazuda, 2012).
How PapersFlow Helps You Research HIV Integrase Inhibitors
Discover & Search
Research Agent uses searchPapers and citationGraph to map 1125-citation Hazuda et al. (2000) as the foundational strand transfer inhibitor paper, revealing 600+ citing works on raltegravir resistance. exaSearch finds dolutegravir trials; findSimilarPapers clusters 50+ papers on intasome structures like Hare et al. (2010).
Analyze & Verify
Analysis Agent applies readPaperContent to extract IC50 values from Summa et al. (2008) raltegravir discovery, then runPythonAnalysis with pandas to compare potency across 20 inhibitors from Hazuda et al. (2000). verifyResponse (CoVe) with GRADE grading scores evidence strength for clinical efficacy claims from Günthard et al. (2016); statistical verification tests weight gain correlations in Sax et al. (2019) datasets.
Synthesize & Write
Synthesis Agent detects gaps in allosteric inhibitor coverage post-2015 papers, flags contradictions between early biochemical assays (Pommier et al., 2005) and cell data (Hazuda et al., 2000). Writing Agent uses latexEditText, latexSyncCitations for 15-paper review, latexCompile for publication-ready manuscript, exportMermaid for resistance mutation pathway diagrams.
Use Cases
"Analyze weight gain data from integrase inhibitor trials vs other ART classes"
Research Agent → searchPapers (Sax 2019) → Analysis Agent → readPaperContent + runPythonAnalysis (pandas plot BMI changes across 5 trials) → matplotlib figure of risk factors output.
"Draft LaTeX review on raltegravir resistance mechanisms with citations"
Research Agent → citationGraph (Summa 2008 hub) → Synthesis Agent → gap detection → Writing Agent → latexEditText (add intasome section) → latexSyncCitations (15 papers) → latexCompile → PDF output.
"Find code for HIV integrase intasome modeling from recent papers"
Research Agent → paperExtractUrls (Hare 2010) → Code Discovery → paperFindGithubRepo → githubRepoInspect (PyMOL scripts for strand transfer) → runPythonAnalysis sandbox execution → structure visualization output.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (integrase inhibitors) → citationGraph (Hazuda 2000 cluster) → DeepScan (7-step verifyResponse on 50 papers) → GRADE-scored report on resistance. Theorizer generates hypotheses on allosteric sites from Hare et al. (2010) + Pommier et al. (2005), chain-of-verification reduces speculation. DeepScan analyzes weight gain meta-data from Sax et al. (2019) + Günthard et al. (2016).
Frequently Asked Questions
What defines HIV Integrase Inhibitors?
These are strand transfer inhibitors blocking HIV-1 DNA integration into host chromatin, exemplified by raltegravir and dolutegravir (Hazuda et al., 2000).
What are key methods for integrase inhibition?
Strand transfer assays measure IC50 in cells; intasome crystal structures guide design (Hare et al., 2010; Summa et al., 2008).
What are the most cited papers?
Hazuda et al. (2000, 1125 citations) on cell-active inhibitors; Arts and Hazuda (2012, 837 citations) on therapy overview; Pommier et al. (2005, 682 citations) on mechanisms.
What open problems exist?
Overcoming integrase mutations, minimizing weight gain (Sax et al., 2019), developing allosteric inhibitors beyond strand transfer active site.
Research HIV/AIDS drug development and treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HIV Integrase Inhibitors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers